Vertex buys in on Stablix's protein stabilization approach in research and licensing deal
25 Apr 2023
License out/inPROTACs
Roughly two years after Stablix embarked on a mission to stabilize certain proteins whose insufficiency leads to disease, Vertex Pharmaceuticals announced it’s coming along for the ride.
Stablix and Vertex unveiled a collaboration on Tuesday that gives Vertex an exclusive license to certain molecules discovered under the pact. Stablix has billed its platform as a “first-in-category” approach that’s essentially the inverse of PROTACs. The idea is to recruit enzymes called deubiquitinases, or DUBs, to restore useful proteins for potential use in rare diseases, oncology and immunology. Stablix is calling their drugs RESTORACs.
Preview
Source: EndPoints
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 166,100+ biopharma pros reading Endpoints daily — and it's free.
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.